首页|肾透明细胞癌肿瘤免疫微环境特征鉴定及预后模型构建

肾透明细胞癌肿瘤免疫微环境特征鉴定及预后模型构建

扫码查看
目的 通过生物信息学方法筛选肾透明细胞癌免疫相关预后基因并探讨肾透明细胞癌肿瘤免疫微环境中各细胞的浸润程度,基于预后基因建立预后风险评分模型.方法 选取癌症基因组图谱(TCGA)数据库中532例基因数据完整的肾透明细胞癌患者,根据差异基因表达分析筛选免疫相关基因,再使用最小绝对收缩和选择算子(Lasso)-Cox分析筛选免疫相关预后基因,并建立预后风险评分公式.使用一致性聚类对TCGA中532例肾透明细胞癌患者划分不同免疫亚组,比较不同免疫亚组间的生存情况及免疫微环境差异.最终基于预后风险得分、年龄和临床分期通过R软件构建1、3、5年预后相关的风险模型,并绘制受试者工作特征(ROC)曲线评估风险模型的预测能力.结果 差异性分析筛选出1 276个免疫相关基因,基于免疫相关基因对研究对象进行一致性聚类,其中免疫亚组1组281例,免疫亚组2组251例.免疫亚组2组患者的预后生存情况优于免疫亚组1组患者,且2个免疫亚组间的免疫细胞浸润程度和相关免疫检查点基因表达差异有统计学意义,均P<0.05.使用LASSO-Cox鉴定出9个免疫相关预后基因以构建预后风险得分,即 IGHV1.3、IGHV1.69D、MANCR、LINC00460、LINC00942、NMB、CPA4、TMEM158 和 PI3K.多因素 Cox 回归分析结果显示,风险评分(HR=9.564,95%CI为3.439~26.600,P<0.001)、临床分期(HR=1.788,95%CI为1.562~2.047,P<0.001)和年龄(HR=1.032,95%CI 为 1.017~1.047,P<0.001)均与预后相关.ROC 结果表明该风险得分对患者的总生存期具有良好的预测性能,其中预后模型的1、3和5年的平均曲线下面积(AUC)分别为0.866(95%CI 为 0.823~0.908)、0.799(95%CI 为 0.752~0.847)、0.765(95%CI 为 0.709~0.821).结论 基于免疫相关基因将患者分为2个免疫亚组,并进一步筛选免疫相关预后基因,构建的预后风险得分能够作为肾透明细胞癌的独立预测因子预测患者预后并且指导临床治疗.
Identification of tumor immune microenvironment of clear cell renal cell carcinoma and construction of prognostic model
Objective To screen immune-related prognostic genes of clear cell renal cell carcinoma(ccRCC)by bioinformat-ics methods and to explore the infiltration degree of each various cells in the tumor immune microenvironment,and to as-sess the prognostic value of immune related prognostic genes.Methods Totally 532 ccRCC patients with complete gene data in the cancer genome atlas(TCGA)database were selected,and immune-related genes were screened according to differential gene expression analysis.Least absolute shrinkage and selection operator(Lasso)-Cox analysis was used to screen immune-related prognostic genes,and a prognostic risk score formula was established.Consistent clustering was used to divide 532 ccRCC patients from the TCGA into different immune subgroups,and the survival status and immune microenvironmental differences between these subgroups were compared.Immune-related genes were identified according to immune scores and matrix scores.We further applied consensus clustering to explore immunological subgroup among included patients and difference in survival and tumor immune microenvironment between different immunological sub-groups.Finally,1-year,3-year and 5-year prognostic models were constructed based on prognostic risk score,age and clinical staging,and the receiver operating characteristic(ROC)curve was drawn to evaluate the predictive ability of the risk model.Results A total of 1 276 immune-related genes were screened by differential analysis,and the subjects were clustered based on immune-related genes,including 281 subjects in immunological subgroup one and 251 subjects in im-munological subgroup two.Patients in immunological subgroup two had significantly better prognosis than patients in im-munological subgroup one.We also found significant difference in the immune infiltrating cells and immune checkpoints between two immunological subgroups(all P<0.05).Nine immune-related prognostic genes were identified using LAS-SO-Cox analysis to construct the prognostic risk score,including IGHV1.3,IGHV1.69D,MANCR,LINC00460,LINC00942,NMB,CPA4,TMEM158 and PI3K.Multivariate Cox regression analysis showed that risk score(HR=9.564,95%CI:3.439-26.600,P<0.001),clinical stage(HR=1.788,95%CI:1.562-2.047,P<0.001),age(HR=1.032,95%CI:1.017-1.047,P<0.001),and they allwere associated with prognosis.ROC analysis showed prognostic risk score had excellent prediction performance,with area under curve(AUC)=0.866(95%CI:0.823-0.908),AUC=0.799(95%CI:0.752-0.847),AUC=0.765(95%CI:0.709-0.821)for 1-year,3-year and 5-year prognostic models,respectively.Conclusions We divided renal clear cell carcinoma patients into two immunological sub-groups,and further identified nine9 immune-related prognostic genes.The prognostic risk score could act as an independ-ent predictor to predict the prognosis of ccRCC patients and guide clinical treatment.

clear cell renal cell carcinomatumor immune microenvironmentprognostic risk scoreprognostic model

李淑婷、谷冰冰、车佳婧、吕嘉丽、王成、张涛、王家林

展开 >

山东大学齐鲁医学院公共卫生学院生物统计系,山东济南 250012

山东省肿瘤防治研究院(山东省肿瘤医院)预防管理部,山东第一医科大学(山东省医学科学院),山东 济南 250017

肾透明细胞癌 肿瘤免疫微环境 风险得分 预后模型

国家自然科学基金

82222064

2024

社区医学杂志
中华预防医学会

社区医学杂志

影响因子:0.588
ISSN:1672-4208
年,卷(期):2024.22(13)